Aptose Biosciences Inc. (APTO)
Company Description
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML.
The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS.
It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014.
Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Country | Canada |
Founded | 1986 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 35 |
CEO | Dr. William G. Rice Ph.D. |
Contact Details
Address: 251 Consumers Road, Suite 1105 Toronto, A6 M2J 4R3 Ontario, Canada | |
Phone | 647-479-9828 |
Website | aptose.com |
Stock Details
Ticker Symbol | APTO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000882361 |
CUSIP Number | 03835T200 |
ISIN Number | CA03835T3091 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. William G. Rice Ph.D. | Chairman, President, Chief Executive Officer and Chief Accounting Officer |
Fletcher Payne | Senior Vice President, Chief Financial Officer, Chief Business Officer and Secretary |
Dr. Rafael Bejar M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
Dr. Marc Wiles Ph.D. | Senior Vice President of Regulatory Affairs |
Brooks Ensign M.B.A. | Vice President and Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | 10-K | Annual Report |
Mar 26, 2024 | 8-K | Current Report |
Mar 18, 2024 | 8-K | Current Report |
Mar 1, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Jan 31, 2024 | 8-K | Current Report |
Jan 30, 2024 | 8-K | Current Report |
Jan 26, 2024 | 424B4 | Prospectus |
Jan 26, 2024 | 8-K | Current Report |